Theragenics Corporation

Theragenics Corporation is a medical device company specializing in brachytherapy and interventional access solutions. They focus on developing products that improve treatment outcomes for prostate cancer and other localized tumors. Founded in 1981 and headquartered in Buford, US, Theragenics Corporation develops medical devices primarily for brachytherapy and other interventional applications. The company has engaged in 2 deals, with its most recent deal on March 1, 2015.

Theragenics specializes in the development and manufacturing of medical devices focused on brachytherapy, interventional access, veterinary surgical applications, and wound closure. Its core products include TheraSeed® and AgX100® brachytherapy seeds, used for treating prostate cancer and localized tumors. These implants deliver targeted radiation therapy directly to cancerous tissue, minimizing damage to surrounding healthy tissues. Additionally, Theragenics offers various interventional devices like introducers and guidewires, serving healthcare providers across North America, Europe, and Asia.

Theragenics generates revenue through the direct sale of its medical devices to healthcare providers, hospitals, and clinics, along with partnerships with medical associations. They operate on a B2B model, where orders are placed for devices like TheraSeed® and AgX100® based on treatment protocols. Their revenue is supported by collaborations that enhance product distribution and a commitment to innovation in their flagship products. Theragenics is focused on expanding its product portfolio and enhancing market presence.

They plan to launch new medical devices tailored for oncology and expand into new markets across Asia and Europe by 2025. Recent funding from their last deal on March 1, 2015, will be utilized to support these initiatives, particularly in product development and market entry strategies.